ALK(SZ:002940) news flash·2025-06-09 10:52Core Viewpoint - The company, Angli Kang (002940.SZ), has experienced significant stock price fluctuations, with a cumulative deviation of over 20% in closing prices over two consecutive trading days, attributed to abnormal trading activity [1] Company Summary - The company confirmed that there are no corrections or supplementary disclosures needed for previously released information, and there have been no significant changes in the internal or external operating environment [1] - The company and its controlling shareholders have not engaged in any stock trading during the period of abnormal price fluctuations [1] - The innovative drug project ALK-N001 is currently in Phase I clinical trials, characterized by a long research and development cycle and substantial investment requirements, indicating potential investment risks for investors [1]